Ibrutinib and nascent recovery of Humoral Immunity
Aue G, Farooqui M, Jones J, et al.
Key Points:
- Investigators present data from phase II trial (NCT01500733)focussing on normal B cell function and immunoglobulin levels
- Trend towards decreased IgG levels (non-statistically significant), rising serum IgA and IgM levels (statistically significant)was observed
- TN patients had higher IgA and IgM levels at baseline and achieved higher absolute increase by 12 months
- There was 76% and 72% reduction of kappa serum free light chain (KSFLC) at 6 and 12 months, and level normalized by 6 months in 7 pts
- Lambda serum free light chains were low prior to therapy; increased by 68% (P<0.005) to normal levels by 6 months in all of them.
Implications:
- Ibrutinib leads to significant increase in IgA and IgM serum levels, with little change in IgG levels, suggesting a beginning recovery of humoral immunity
- Reduction of clonal light chains with increasing levels of non-clonal light chain raises possibility that ibrutinib may selectively target CLL cells while allowing re-growth of normal B-cells.
View the original abstract on the ASH website.
